Browsing Tag
Kahn Swick & Foti
5 posts
ADMA Biologics stock has jumped 13% in a week, so why does the August 10 lawsuit deadline still matter?
ADMA Biologics is approaching an August 10 lead-plaintiff deadline in a securities class action at a moment when stronger ASCENIV sales, higher margins and improved cash generation are complicating the investment narrative.
BioSig Technologies faces shareholder scrutiny over Streamex merger terms
BioSig's merger with Streamex Exchange cuts shareholder stake to 25%—find out why legal experts and investors are raising red flags.
Why NET Power faces a class action lawsuit over Project Permian cost overruns and delays
NET Power shareholders face a June 17 deadline to join a class action lawsuit over $2B Project Permian costs and a 2029 delay. Learn what’s at stake.
Why Iovance Biotherapeutics faces a class action lawsuit after a 45% stock crash
Iovance faces a class action lawsuit after cutting 2025 revenue guidance by 40%. Learn what triggered the stock’s 45% drop and how investors can file claims.
Red Cat Holdings Lawsuit puts defense drone valuations under spotlight amid investor turmoil
RCAT stock dropped 21% after fraud allegations tied to a U.S. Army contract. Learn what’s next for investors ahead of the July 22, 2025, class action deadline.